Kamada Ltd., a biopharmaceutical company specializing in plasma-derived therapeutics, has reported a notable financial upturn in 2024, with annual revenues reaching $161 million, marking a 13% increase from the previous year. The company's net income also saw a substantial rise of 75%, underscoring its robust financial health. This performance is largely attributed to the strong demand for its FDA-approved therapies, including KEDRAB® and CYTOGAM®, which cater to niche medical needs such as rabies prevention and organ transplant support.
In a move that reflects its financial stability, Kamada announced a special cash dividend of 20 cents per share. Looking ahead, the company is optimistic about sustaining double-digit growth, projecting revenues between $178 million and $182 million in 2025. This forecast represents a 12% year-over-year growth, signaling confidence in its operational and strategic direction.
Strategic expansions are at the forefront of Kamada's growth agenda. The company plans to introduce biosimilar products in Israel, aiming to launch 1-3 products annually with the goal of generating $15-20 million in sales within five years. Additionally, Kamada is enhancing its plasma collection capabilities with a new facility in San Antonio, Texas, expected to contribute $8-10 million annually to its revenue stream.
Internationally, Kamada has secured a $25 million contract to supply KAMRAB® and VARIZIG® in South America from 2025 through 2027, showcasing its expanding global footprint. The company is also exploring mergers, acquisitions, and other business development opportunities to fuel further growth.
A significant future opportunity for Kamada lies in its phase 3 trial of an inhaled alpha-1 antitrypsin (AAT) therapy, targeting a genetic disorder that can lead to lung damage. With an estimated market potential of over $2 billion, this therapy could mark a pivotal commercial breakthrough for the company upon approval.
CEO Amir London has emphasized Kamada's dedication to innovation and global expansion as key drivers of its multi-year growth strategy. By capitalizing on its expertise in plasma-derived therapeutics and pursuing strategic initiatives, Kamada is well-positioned for sustained success in the competitive biopharmaceutical landscape.
